Virginia Ferraresi

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, N. Abecassis, Sebastian Bauer et al. · Annals of Oncology · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pathology +17

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Pharmacology +7

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · New England Journal of Medicine · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015 · 1.3K citations

Medicine, Oncology, Immunotherapy +15